For a number of reasons, including high toxicity, only a few PI3K-AKT-mTOR pathway inhibitors have been approved by the FDA and indicated for cancer treatment: four PI3K inhibitors—idelalisib, copanlisib and, more recently, duvelisib and alpelisib (September 2018 and May 2019, respectively); one AKT inhibitor—miltefosine; and, two mTOR inhibitors—temsirolimus and everolimus. This evidence concerns the gene AKT1 and cancer.